[Controlled study of the effect of silymarin on alcoholic liver disease].
A controlled trial on the use of Silymarin in patients with alcoholic liver disease was performed. Seventy two patients were admitted to the trial and randomly assigned to an experimental or controls group. Experimentals received 280 mg/day of Silymarin and controls an equal number of placebo tablet...
Guardado en:
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
1992
|
| Materias: | |
| Acceso en línea: | Ver en el sistema de origen Enlace permanente (DOI o Handle) |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1881508868374134784 |
|---|---|
| author | Bunout, Daniel Hirsch, Sandra Petermann, Marcus de la Maza, María Pía Silva, G Kelly, Matt Vizcarra Ugarte, German Alex Iturriaga, H |
| author_browse | Bunout, Daniel Hirsch, Sandra Iturriaga, H Kelly, Matt Petermann, Marcus Silva, G Vizcarra Ugarte, German Alex de la Maza, María Pía |
| author_facet | Bunout, Daniel Hirsch, Sandra Petermann, Marcus de la Maza, María Pía Silva, G Kelly, Matt Vizcarra Ugarte, German Alex Iturriaga, H |
| author_sort | Bunout, Daniel |
| collection | Producción científica |
| description | A controlled trial on the use of Silymarin in patients with alcoholic liver disease was performed. Seventy two patients were admitted to the trial and randomly assigned to an experimental or controls group. Experimentals received 280 mg/day of Silymarin and controls an equal number of placebo tablets. Three patients on placebo and nine on Silymarin were lost from control (p = 0.035), remaining in control 34 patients receiving placebo and 25 patients receiving the drug. Both groups did not differ in their initial laboratory assessment and were followed up for an average of 15 months. Ten patients died during the follow up (5 in placebo and 5 in Silymarin); life table analysis did not show significant differences in mortality. Patients who died had lower serum albumin and prothrombin time and higher total bilirubin, alkaline phosphatases and CCLI on the initial clinical and laboratory assessment. Final laboratory values and their changes in those who survived did not differ between Silymarin and placebo. Twenty two patients on placebo (65%) and 14 on Silymarin (58%) recognized alcohol ingestion or had a positive urine sample analysis for alcohol during follow up. Those who abstained from alcohol had a significant fall in gamma glutamyl transferase during follow up. No other significant differences were observed between these two groups. It is concluded that in this trial, Silymarin did not change the evolution or mortality of alcoholic liver disease. |
| format | Article |
| id | oai:cris.upeu.edu.pe:20.500.15037/1665 |
| institution | UPeU |
| language | English |
| publishDate | 1992 |
| publishDateRange | 1992 |
| publishDateSort | 1992 |
| record_format | dspace |
| spelling | oai:cris.upeu.edu.pe:20.500.15037/16652026-10-30T16:16:25Z[Controlled study of the effect of silymarin on alcoholic liver disease].Bunout, DanielHirsch, SandraPetermann, Marcusde la Maza, María PíaSilva, GKelly, MattVizcarra Ugarte, German AlexIturriaga, HPlaceboMedicineInternal medicineAlcoholic liver diseaseGastroenterologyIngestionAlcoholic hepatitisAlcoholBilirubinLiver diseaseAlbuminRandomized controlled trialSurgeryCirrhosisPathologyChemistryAlternative medicineBiochemistryDouble-Blind MethodFemaleHumansLiver Diseases, Alcoholic bloodLiver Diseases, Alcoholic drug therapyLiver Diseases, Alcoholic mortalityLiver Function TestsMaleMiddle AgedPatient ComplianceSilymarin adverse effectsSilymarin therapeutic useTemperanceTreatment OutcomeHealth Sciences Medicine Pathology and Forensic Medicine Alcohol Consumption and Health EffectsHealth Sciences Medicine Pulmonary and Respiratory Medicine Silymarin and Mushroom PoisoningLife Sciences Pharmacology, Toxicology and Pharmaceutics Pharmacology Drug-Induced Hepatotoxicity and ProtectionA controlled trial on the use of Silymarin in patients with alcoholic liver disease was performed. Seventy two patients were admitted to the trial and randomly assigned to an experimental or controls group. Experimentals received 280 mg/day of Silymarin and controls an equal number of placebo tablets. Three patients on placebo and nine on Silymarin were lost from control (p = 0.035), remaining in control 34 patients receiving placebo and 25 patients receiving the drug. Both groups did not differ in their initial laboratory assessment and were followed up for an average of 15 months. Ten patients died during the follow up (5 in placebo and 5 in Silymarin); life table analysis did not show significant differences in mortality. Patients who died had lower serum albumin and prothrombin time and higher total bilirubin, alkaline phosphatases and CCLI on the initial clinical and laboratory assessment. Final laboratory values and their changes in those who survived did not differ between Silymarin and placebo. Twenty two patients on placebo (65%) and 14 on Silymarin (58%) recognized alcohol ingestion or had a positive urine sample analysis for alcohol during follow up. Those who abstained from alcohol had a significant fall in gamma glutamyl transferase during follow up. No other significant differences were observed between these two groups. It is concluded that in this trial, Silymarin did not change the evolution or mortality of alcoholic liver disease.Articlehttps://pubmed.ncbi.nlm.nih.gov/1343377https://hdl.handle.net/20.500.15037/1665W195697369enPubMed1992-12-012026-06-13T14:18:12Z2026-06-13T14:18:12Z |
| spellingShingle | Placebo Medicine Internal medicine Alcoholic liver disease Gastroenterology Ingestion Alcoholic hepatitis Alcohol Bilirubin Liver disease Albumin Randomized controlled trial Surgery Cirrhosis Pathology Chemistry Alternative medicine Biochemistry Double-Blind Method Female Humans Liver Diseases, Alcoholic blood Liver Diseases, Alcoholic drug therapy Liver Diseases, Alcoholic mortality Liver Function Tests Male Middle Aged Patient Compliance Silymarin adverse effects Silymarin therapeutic use Temperance Treatment Outcome Health Sciences Medicine Pathology and Forensic Medicine Alcohol Consumption and Health Effects Health Sciences Medicine Pulmonary and Respiratory Medicine Silymarin and Mushroom Poisoning Life Sciences Pharmacology, Toxicology and Pharmaceutics Pharmacology Drug-Induced Hepatotoxicity and Protection Bunout, Daniel Hirsch, Sandra Petermann, Marcus de la Maza, María Pía Silva, G Kelly, Matt Vizcarra Ugarte, German Alex Iturriaga, H [Controlled study of the effect of silymarin on alcoholic liver disease]. |
| title | [Controlled study of the effect of silymarin on alcoholic liver disease]. |
| title_full | [Controlled study of the effect of silymarin on alcoholic liver disease]. |
| title_fullStr | [Controlled study of the effect of silymarin on alcoholic liver disease]. |
| title_full_unstemmed | [Controlled study of the effect of silymarin on alcoholic liver disease]. |
| title_short | [Controlled study of the effect of silymarin on alcoholic liver disease]. |
| title_sort | controlled study of the effect of silymarin on alcoholic liver disease |
| topic | Placebo Medicine Internal medicine Alcoholic liver disease Gastroenterology Ingestion Alcoholic hepatitis Alcohol Bilirubin Liver disease Albumin Randomized controlled trial Surgery Cirrhosis Pathology Chemistry Alternative medicine Biochemistry Double-Blind Method Female Humans Liver Diseases, Alcoholic blood Liver Diseases, Alcoholic drug therapy Liver Diseases, Alcoholic mortality Liver Function Tests Male Middle Aged Patient Compliance Silymarin adverse effects Silymarin therapeutic use Temperance Treatment Outcome Health Sciences Medicine Pathology and Forensic Medicine Alcohol Consumption and Health Effects Health Sciences Medicine Pulmonary and Respiratory Medicine Silymarin and Mushroom Poisoning Life Sciences Pharmacology, Toxicology and Pharmaceutics Pharmacology Drug-Induced Hepatotoxicity and Protection |
| topic_facet | Placebo Medicine Internal medicine Alcoholic liver disease Gastroenterology Ingestion Alcoholic hepatitis Alcohol Bilirubin Liver disease Albumin Randomized controlled trial Surgery Cirrhosis Pathology Chemistry Alternative medicine Biochemistry Double-Blind Method Female Humans Liver Diseases, Alcoholic blood Liver Diseases, Alcoholic drug therapy Liver Diseases, Alcoholic mortality Liver Function Tests Male Middle Aged Patient Compliance Silymarin adverse effects Silymarin therapeutic use Temperance Treatment Outcome Health Sciences Medicine Pathology and Forensic Medicine Alcohol Consumption and Health Effects Health Sciences Medicine Pulmonary and Respiratory Medicine Silymarin and Mushroom Poisoning Life Sciences Pharmacology, Toxicology and Pharmaceutics Pharmacology Drug-Induced Hepatotoxicity and Protection |
| url | https://pubmed.ncbi.nlm.nih.gov/1343377 https://hdl.handle.net/20.500.15037/1665 |
| work_keys_str_mv | AT bunoutdaniel controlledstudyoftheeffectofsilymarinonalcoholicliverdisease AT hirschsandra controlledstudyoftheeffectofsilymarinonalcoholicliverdisease AT petermannmarcus controlledstudyoftheeffectofsilymarinonalcoholicliverdisease AT delamazamariapia controlledstudyoftheeffectofsilymarinonalcoholicliverdisease AT silvag controlledstudyoftheeffectofsilymarinonalcoholicliverdisease AT kellymatt controlledstudyoftheeffectofsilymarinonalcoholicliverdisease AT vizcarraugartegermanalex controlledstudyoftheeffectofsilymarinonalcoholicliverdisease AT iturriagah controlledstudyoftheeffectofsilymarinonalcoholicliverdisease |